The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 13, 2022

Filed:

Oct. 30, 2018
Applicant:

Eisai R&d Management Co., Ltd., Tokyo, JP;

Inventors:

Daniel Aird, Reading, MA (US);

Laura Corson, Brookline, MA (US);

Ping Zhu, Boxboro, MA (US);

Markus Warmuth, Newton, MA (US);

Silvia Buonamici, Boston, MA (US);

Peter Gerard Smith, Arlington, MA (US);

Peter Fekkes, Waltham, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/496 (2006.01); A61P 35/00 (2006.01); A61K 31/05 (2006.01); A61K 31/11 (2006.01); A61K 31/166 (2006.01); A61K 31/343 (2006.01); A61K 31/352 (2006.01); A61K 31/395 (2006.01); A61K 31/404 (2006.01); A61K 31/426 (2006.01); A61K 31/4355 (2006.01); A61K 31/4725 (2006.01); A61K 31/495 (2006.01); A61K 31/5355 (2006.01);
U.S. Cl.
CPC ...
A61K 31/496 (2013.01); A61K 31/05 (2013.01); A61K 31/11 (2013.01); A61K 31/166 (2013.01); A61K 31/343 (2013.01); A61K 31/352 (2013.01); A61K 31/395 (2013.01); A61K 31/404 (2013.01); A61K 31/426 (2013.01); A61K 31/4355 (2013.01); A61K 31/4725 (2013.01); A61K 31/495 (2013.01); A61K 31/5355 (2013.01); A61P 35/00 (2018.01);
Abstract

The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.


Find Patent Forward Citations

Loading…